CoChat
Sign Up
Cited by 292Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorParkinson's Disease Mechanisms and Treatments

Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study

Open access
Howes, O, Bose, S, Turkheimer, F, Valli, I, Egerton, A, Stahl, D, Valmaggia, L, Allen, P +2 more·2011·Molecular Psychiatry
DOI 10.1038/mp.2011.20PMC PMC3662873
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mp.2011.20

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In CHR subjects in general, as well as in the subgroup that later become psychotic, the greatest alterations in dopamine synthesis and release capacity have been found in the associative striatum, paralleling findings in psychotic patients.

    “In CHR subjects in general, as well as in the subgroup that later become psychotic, the greatest alterations in dopamine synthesis and release capacity have been found in the associative striatum (57-59, 62), paralleling findings in psychotic patients(50, 69).”

    From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [58]

    The PET study’s results (main text; page not supplied) place the significant longitudinal increase in dopamine synthesis capacity among participants who developed psychosis in the sensorimotor striatum, not the associative striatum, where the change was not significant. The paper does not report a measure of dopamine release capacity, so it cannot support that additional part of the claim. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

  • CHR subjects show increased dopamine synthesis capacity relative to healthy controls with effect sizes of about 0.8 in the striatum, and in its associative and sensorimotor but not limbic sub-divisions.

    “In contrast, CHR subjects show increased dopamine synthesis capacity relative to HC with effect sizes of about 0.8 in the striatum (57-59), and its associative (57-59, 62) and sensorimotor (58, 59), but not limbic sub-divisions.”

    From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [58]

    In the paper’s introductory text (page unavailable), the authors state that striatal dopamine synthesis capacity is increased when people first present with ultra-high-risk symptoms. The paper does not report the claimed effect size of about 0.8 relative to healthy controls or establish the stated pattern across associative, sensorimotor, and limbic subdivisions; its subdivision results concern longitudinal change as some participants developed psychosis. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Howes et al. (58) found increased dopamine synthesis capacity in the striatum in clinical high risk individuals who developed psychosis compared to healthy controls, with an effect size of 1.18.

    “Howes et al. | 9 CHR-T | [ 18 F]-DOPA | dopamine synthesis | Striatum | CHR | 1.18 |”

    From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [58]

    The paper’s main text (page not provided) reports a longitudinal increase in dopamine synthesis capacity in the sensorimotor striatum of eight high-risk participants who developed psychosis. It does not report the claimed comparison with healthy controls: its comparison is between scans of the same participants, and the reported effect size is 1.125, not 1.18. The striatum as a whole did not show a significant change. (LLM, conf=0.92)

    Experimental — accuracy not yet measured

  • Striatal dopamine changes are secondary to other defects and preventive treatments should aim for an earlier developmental window for course alteration.

    “Indeed, since dopamine is already elevated in some patients when they first seek help 52 , it is conceivable that striatal dopamine changes are secondary to other defects and preventive treatments should aim for an earlier developmental window for course alteration.”

    From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [52]

  • Levels of striatal dopamine increase progressively as subjects make the transition from high-risk to psychosis.

    “Longitudinal imaging studies in humans have shown that levels of striatal dopamine increases progressively as subjects make the transition from high-risk to psychosis 52 .”

    From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [52]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 11

  1. [1]Gur RE Keshavan MS Lawrie SM Schizophr Bull 2007 33 921 931 17548845 PMC2632317
  2. [2]Meisenzahl EM Schmitt GJ Scheuerecker J Moller HJ Int Rev Psychiatry 2007 19 337 345 17671867
  3. [4]Heinz A Romero B Gallinat J Juckel G Weinberger DR Pharmacopsychiatry 2003 36 S152 S157 14677072
  4. [5]Howes OD Egerton A Allan V McGuire P Stokes P Kapur S Curr Pharm Des 2009 15 2550 2559 19689327 PMC3687204
  5. [6]Laruelle M Abi-Dargham A Gil R Kegeles L Innis R Biol Psychiatry 1999 46 56 72 10394474
  6. [7]Yung AR Yuen HP McGorry PD Aust.N.Z.J.Psychiatry 2005 39 964 971 16343296
  7. [8]Cannon TD Cadenhead K Cornblatt B Arch.Gen.Psychiatry 2008 65 28 37 18180426 PMC3065347
  8. [9]Howes OD Montgomery AJ Asselin MC Arch Gen Psychiatry 2009 66 13 20 19124684
  9. [10]Howes OD Montgomery AJ Asselin MC Murray RM Grasby PM McGuire PK Br J Psychiatry Suppl 2007 51 s13 18 18055930 PMC3796874
  10. [11]McGlashan TH Zipursky RB Perkins D Am.J Psychiatry 2006 163 790 799 16648318
  11. [12]McGorry PD Yung AR Phillips LJ Arch.Gen.Psychiatry 2002 59 921 928 12365879

Cited by

Sorted by citations

Related

Authors
Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., Valmaggia, L., Allen, P., Murray, R., & McGuire, P.
Corresponding author
Howes, O
ORCID
Venue
Molecular Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2011-03-01
Volume
16
Issue
9
Pages
885-886
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
DOI
10.1038/mp.2011.20
PMC
PMC3662873
OpenAlex
W2047016005
Cited by
292
References
13
Citations by year
2026: 7 · 2025: 13 · 2024: 12 · 2023: 18 · 2022: 23 · 2021: 21 · 2020: 28 · 2019: 18 · 2018: 16 · 2017: 17 · 2016: 26 · 2015: 15 · 2014: 24 · 2013: 23 · 2012: 22
FWCI
16.73
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Research Portal (King's College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
striatal dopamine synthesis, psychosis, schizophrenia, dopamine synthesis capacity, striatum, positron emission tomography
MeSH terms
Adult, Corpus Striatum, Dihydroxyphenylalanine, Dopamine, Female, Fluorine Radioisotopes, Humans, Male, Psychotic Disorders, Positron-Emission Tomography, Functional Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review